A French biotech company has announced an agreement with a center for biomedical research of which it is a spin-off.
Oncovita has entered into a licensing agreement with Institut Pasteur (pictured above), granting it an exclusive worldwide license to develop, manufacture and commercialize therapies based on the immuno-oncolytic measles virus platform.
The licensed technology is based on changes in the measles viral genome designed to dramatically increase its anti-tumor properties. This technology has been developed by the viral genomics and vaccination unit of Institut Pasteur in Paris.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze